Adding bemarituzumab to chemotherapy as first-line treatment for advanced gastric and gastroesophageal junction (GEJ) cancers improved survival over chemotherapy alone in the phase 2 FIGHT trial.
Among 155 patients followed for a median of 10.9 months, the combination of bemarituzumab and modified FOLFOX chemotherapy (leucovorin, fluorouracil, and oxaliplatin) resulted in a median progression-free survival (PFS) of 9.5 months, compared with 7.4 months with chemotherapy alone.